MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. (Q34565346)

3 August 2017

title

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. (English)

1 reference

3 August 2017

1 reference

Hans Olsson

1

1 reference

3 August 2017

Per Hultman

2

1 reference

3 August 2017

Johan Rosell

3

1 reference

3 August 2017

Peter Söderkvist

4

1 reference

3 August 2017

Staffan Jahnson

5

1 reference

3 August 2017

publication date

28 January 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

page(s)

5

1 reference

Creative Commons Attribution 2.0 Generic

3 August 2017

copyright license

start time

28 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Immunohistochemical evaluation of cell cycle regulators: impact on predicting prognosis in stage t1 urinary bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Recent advances in p53 research and cancer treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

The RP-Mdm2-p53 pathway and tumorigenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

CREG1 enhances p16(INK4a) -induced cellular senescence

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

p53: the attractive tumor suppressor in the cancer research field

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Reactivation of p53: from peptides to small molecules.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Optimal timing of radical cystectomy in T1 high-grade bladder cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Shaping genetic alterations in human cancer: the p53 mutation paradigm

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Lymphovascular invasion as a prognostic tool for advanced bladder cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

The MDM2-p53 interaction.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

p53 mutations in urinary bladder cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

7 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-13-5

Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-13-5

MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-13-5

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-13-5

Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-13-5

Screening for Mutations in DNA by Single-Stranded Conformation Polymorphism (SSCP) Analysis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3574032

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

27 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-13-5

A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival

21 January 2018

1 reference

12 December 2020

Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history

1 reference

12 December 2020

Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression

1 reference

12 December 2020

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis

1 reference

12 December 2020

Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer

1 reference

12 December 2020

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia

1 reference

12 December 2020

Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer

1 reference

12 December 2020

Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?

1 reference

12 December 2020

MDM2 T309G polymorphism is associated with bladder cancer

1 reference

12 December 2020

Association of breast cancer outcome with status of p53 and MDM2 SNP309

1 reference

12 December 2020

p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy

1 reference

12 December 2020

Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods

1 reference

12 December 2020

Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder

1 reference

12 December 2020

Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours

1 reference

12 December 2020

P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2490-13-5

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference